title: The immune-stimulating peptide WKYMVm has therapeutic effects against ulcerative colitis.
abstract: In this study, we examined the therapeutic effects of an immune-stimulating peptide, WKYMVm, in ulcerative colitis. The administration of WKYMVm to dextran sodium sulfate (DSS)-treated mice reversed decreases in body weight, bleeding score and stool score in addition to reversing DSS-induced mucosa destruction and shortened colon. The WKYMVm-induced therapeutic effect against ulcerative colitis was strongly inhibited by a formyl peptide receptor (FPR) 2 antagonist, WRWWWW, indicating the crucial role of FPR2 in this effect. Mechanistically, WKYMVm effectively decreases intestinal permeability by stimulating colon epithelial cell proliferation. WKYMVm also strongly decreases interleukin-23 and transforming growth factor-β production in the colon of DSS-treated mice. We suggest that the potent immune-modulating peptide WKYMVm and its receptor FPR2 may be useful in the development of efficient therapeutic agents against chronic intestinal inflammatory diseases.
authors.affiliation: 1] Department of Biological Science, Sungkyunkwan University, Suwon, Korea [2] Mitochondria Hub Regulation Center, College of Medicine, Dong-A University, Busan, Korea.
authors.forename: Sang Doo
authors.initials: SD
authors.lastname: Kim
authors.forename: Soonil
authors.initials: S
authors.lastname: Kwon
authors.forename: Sung Kyun
authors.initials: SK
authors.lastname: Lee
authors.forename: Minsoo
authors.initials: M
authors.lastname: Kook
authors.forename: Ha Young
authors.initials: HY
authors.lastname: Lee
authors.forename: Ki-Duk
authors.initials: KD
authors.lastname: Song
authors.forename: Hak-Kyo
authors.initials: HK
authors.lastname: Lee
authors.forename: Suk-Hwan
authors.initials: SH
authors.lastname: Baek
authors.forename: Chan Bae
authors.initials: CB
authors.lastname: Park
authors.forename: Yoe-Sik
authors.initials: YS
authors.lastname: Bae
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D018938:Caco-2 Cells; D049109:Cell Proliferation; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000378:metabolism; D003106:Colon / Q000473:pathology; D006801:Humans; D053759:Interleukin-23 / Q000235:genetics / Q000378:metabolism; D007413:Intestinal Mucosa / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D009842:Oligopeptides / Q000494:pharmacology / Q000627:therapeutic use*; D010539:Permeability; D044042:Receptors, Formyl Peptide / Q000037:antagonists & inhibitors; D016212:Transforming Growth Factor beta / Q000235:genetics / Q000378:metabolism
chemical_list: D000276:Adjuvants, Immunologic; D053759:Interleukin-23; D009842:Oligopeptides; D044042:Receptors, Formyl Peptide; D016212:Transforming Growth Factor beta; C113617:Trp-Lys-Tyr-Met-Val-Met; C481578:formyl peptide receptor 2, mouse; C509690:tryptophyl-arginyl-tryptophyl-tryptophyl-tryptophyl-tryptophanamide
references.citation: EMBO J. 1999 Mar 1;18(5):1280-91
references.pmid: 10064594
references.citation: Gastroenterology. 1996 Apr;110(4):975-84
references.pmid: 8613031
references.citation: J Immunol. 2004 Jul 1;173(1):607-14
references.pmid: 15210823
references.citation: J Leukoc Biol. 1999 Feb;65(2):241-8
references.pmid: 10088607
references.citation: Nat Rev Immunol. 2008 Jun;8(6):458-66
references.pmid: 18500230
references.citation: Mol Pharmacol. 2003 Oct;64(4):841-7
references.pmid: 14500740
references.citation: J Immunol. 1991 Sep 15;147(6):1940-6
references.pmid: 1653806
references.citation: Nat Rev Immunol. 2011 Jan;11(1):9-20
references.pmid: 21151034
references.citation: Lancet. 2008 Jul 5;372(9632):67-81
references.pmid: 18603161
references.citation: J Immunol. 2007 Dec 15;179(12):8112-21
references.pmid: 18056353
references.citation: J Immunol. 2000 Oct 15;165(8):4598-605
references.pmid: 11035102
references.citation: Immunol Rev. 2008 Dec;226:147-59
references.pmid: 19161422
references.citation: J Immunol. 2002 May 15;168(10):5260-7
references.pmid: 11994483
references.citation: Exp Mol Med. 2004 Apr 30;36(2):135-44
references.pmid: 15150442
references.citation: Nat Immunol. 2009 Jun;10(6):603-9
references.pmid: 19448631
references.citation: J Immunol. 2009 Nov 1;183(9):5511-7
references.pmid: 19843937
references.citation: J Immunol. 2010 Oct 1;185(7):4302-10
references.pmid: 20817875
references.citation: Inflamm Bowel Dis. 2008 May;14(5):709-20
references.pmid: 18095316
references.citation: J Biol Chem. 2001 Jun 15;276(24):21585-93
references.pmid: 11285256
references.citation: Am J Pathol. 1995 Jan;146(1):264-75
references.pmid: 7856732
references.citation: Am J Physiol Cell Physiol. 2003 Apr;284(4):C888-96
references.pmid: 12456400
references.citation: J Immunol. 1997 Feb 15;158(4):1895-901
references.pmid: 9029131
references.citation: J Immunol. 1999 Dec 15;163(12):6777-84
references.pmid: 10586077
references.citation: Nature. 1992 Oct 22;359(6397):693-9
references.pmid: 1436033
references.citation: Lancet. 2007 May 12;369(9573):1627-40
references.pmid: 17499605
references.citation: Ann N Y Acad Sci. 2012 Jul;1258:159-65
references.pmid: 22731729
references.citation: Inflamm Bowel Dis. 2011 Jan;17(1):362-81
references.pmid: 20725949
references.citation: J Clin Invest. 2013 Apr;123(4):1694-704
references.pmid: 23454745
references.citation: Nature. 2007 Jul 26;448(7152):427-34
references.pmid: 17653185
references.citation: Inflamm Bowel Dis. 2010 Oct;16(10):1808-13
references.pmid: 20222127
references.citation: Gastroenterology. 2009 Jan;136(1):257-67
references.pmid: 18992745
references.citation: J Biol Chem. 1996 Apr 5;271(14):8170-5
references.pmid: 8626507
references.citation: Expert Rev Gastroenterol Hepatol. 2012 Apr;6(2):223-37
references.pmid: 22375527
references.citation: J Leukoc Biol. 1999 Dec;66(6):915-22
references.pmid: 10614772
references.citation: Immunity. 2000 Feb;12(2):171-81
references.pmid: 10714683